| Identification | Back Directory | [Name]
Adomeglivant | [CAS]
1488363-78-5 | [Synonyms]
LY-2409021
Adomeglivant
β-Alanine, N-[4-[(1S)-1-[[4'-(1,1-dimethylethyl)-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]- | [Molecular Formula]
C32H36F3NO4 | [MDL Number]
MFCD30343860 | [MOL File]
1488363-78-5.mol | [Molecular Weight]
555.63 |
| Chemical Properties | Back Directory | [Boiling point ]
656.7±55.0 °C(Predicted) | [density ]
1.173±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);179.97(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);179.97(Max Conc. mM) | [form ]
A solid | [pka]
4.28±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Adomeglivant is a glucagon receptor antagonist used in the combined treatment of type 2 diabetes. | [in vivo]
Adomeglivant (5 mg/kg; i.p.) completely abolishes the hyperglycaemic action of CNO (clozapine-N-oxide) in Avpires-Cre+ mice. (CNO is a specific, pharmacologically inert agonist for hM3Dq-induced membrane depolarisation and increased the firing rate in hM3Dq-expressing arginine-vasopressin (AVP) neurons.)[3]
| Animal Model: | Avpires-Cre+ mice[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection, 30 minutes prior to CNO | | Result: | Completely abolished the hyperglycaemic action of CNO. |
| [storage]
Store at -20°C |
|
| Company Name: |
InvivoChem
|
| Telephone: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|